PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Enlicitide decanoate (MK-0616)

CORALreef Outcomes: enlicitide decanoate (MK-0616) in patients at high cardiovascular risk (NCT06008756)

CORALreef Outcomes: enlicitide decanoate (MK-0616) in patients at high cardiovascular risk (NCT06008756)

Study title/design: CORALreef Outcomes: enlicitide decanoate (MK-0616) in patients at high cardiovascular risk (NCT06008756) Trial NCT06008756/MK-0616-015 (Recruiting). Estimated primary completion: 29 November 2029. Estimated study completion: 29 November 2029. Aim To evaluate the efficacy of enlicitide decanoate (MK-0616) compared to placebo in increasing the time…

read more »
Posted on 27 August 2024 | Posted in Enlicitide decanoate (MK-0616)
CORALreef HeFH: enlicitide decanoate (MK-0616) in adults with familial hypercholesterolaemia (CORALreef HeFH, NCT05952869)

CORALreef HeFH: enlicitide decanoate (MK-0616) in adults with familial hypercholesterolaemia (CORALreef HeFH, NCT05952869)

Study title/design: CORALreef HeFH: enlicitide decanoate (MK-0616) in adults with familial hypercholesterolaemia (CORALreef HeFH, NCT05952869) Trial NCT05952869/MK-0616-017 (Active, not recruiting). Estimated primary completion: 28 April 2025. Estimated study completion: 28 April 2025. Aim To evaluate the efficacy, safety and tolerability of enlicitide decanoate (MK-0616) in…

read more »
Posted on 27 August 2024 | Posted in Enlicitide decanoate (MK-0616)
CORALreef Lipids: enlicitide decanoate (MK-0616) in hypercholesterolaemia (NCT059528456)

CORALreef Lipids: enlicitide decanoate (MK-0616) in hypercholesterolaemia (NCT059528456)

Study title/design: CORALreef Lipids: enlicitide decanoate (MK-0616) in hypercholesterolaemia (NCT059528456) Trial NCT059528456/MK-0616-013 (Active, not recruiting). Estimated primary completion: 15 August 2025. Estimated study completion: 15 August 2025. Aim To evaluate the efficacy, safety and tolerability of enlicitide decanoate (MK-0616) in lowering LDL-C in adults with…

read more »
Posted on 27 August 2024 | Posted in Enlicitide decanoate (MK-0616)
Efficacy and safety of enlicitide decanoate (MK-0616) in hypercholesterolaemia (NCT05261126)

Efficacy and safety of enlicitide decanoate (MK-0616) in hypercholesterolaemia (NCT05261126)

Study title/design: Efficacy and safety of enlicitide decanoate (MK-0616) in hypercholesterolaemia (NCT05261126) Trial  NCT05261126/MK-0616-008 (Completed) Aim To assess the efficacy and safety of enlicitide decanoate (MK-0616) in lowering LDL-C in adults with hypercholesterolaemia Study design Phase 2b, randomised, double-blind, placebo-controlled study of oral MK-0616 6…

read more »
Posted on 27 August 2024 | Posted in Enlicitide decanoate (MK-0616)

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.
Educational Partners and Supporters
AstraZeneca

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation

LIB Therapeutics

Novartis

Sanofi

© Copyright 2025 PCSK9 Forum. All rights reserved